ANAB AnaptysBio, Inc. Common Stock
XNAS
48.77
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ANAB
$48.77
—
Key stats
$48.77
- 52-Week Range
- $30.27 – $73.30
- YTD
- +8.50%
- IV Rank (30D)
- 75.87
- Straddle Price
- $44.70
- P/C Vol Ratio
- 1.66
- Market Cap
- $1.5B
- Open
- $48.97
- Day Range
- $47.98 – $49.62
- Volume
- 417,196
- Prev Close
- $48.73
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 0.76 |
| Cost of Equity (CAPM) | 8.74% (VRP-adj) |
| WACC | 8.91% |
| Volatility Risk Premium | +186.8pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +14.8% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.0B |
| Return on Equity (TTM) | -210.1% |
| Book / Price | 0.9% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | 1.9% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $52.51 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $47.73 |
| Bollinger Width / SMA20 | 27.0% (drives anchor stability) |
| Net Debt | $-0.2B |
| Market Cap | $1B |
Peers used for multiples: AMGN, BIIB, EXEL, GILD, NTRA, REGN, RPRX, VRTX
60-Day Conviction
72%
20-Day Fair Value
≈ by Nov 25, 2026
$48.56
α -0.4%
rank 51%
conviction
27%
40-Day Fair Value
≈ by Dec 24, 2026
$49.48
α +1.5%
rank 56%
conviction
49%
60-Day Fair Value
≈ by Jan 22, 2027
$49.99
α +2.5%
rank 49%
conviction
72%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $13.65 | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 28.7× · 6 peers |
| Peer EV/EBITDA | $38.70 | 10% | median 19.1× · 7 peers |
| Peer P/B | $3.37 | 13% | median 7.6× · 8 peers |
| Peer P/S | $57.26 | 13% | median 6.5× · 8 peers |
| Market Anchor (SMA50) | $52.51 | 49% | stability 77% (BB-width) |
| Options Expected (B-L 30d) | $48.73 | 16% | 10 strikes · skew -0.34 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $1.5B
- Employees
- 104
- List Date
- 2017-01-26
- CIK
- 0001370053
- Next Earnings
- 2026-11-03 (After-Close)
- EPS Forecast
- $0.41 (3 est.)
- Headquarters
- San Diego, CA
- Homepage
- https://www.anaptysbio.com
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 10.96% | -11.05% | -14.82% | 8.76% | 34.21% | 5.47% | 5.59% |
| Feb | 10.64% | -4.08% | -0.20% | 5.28% | 0.96% | 8.92% | 3.59% |
| Mar | -23.17% | -18.21% | -13.44% | -11.51% | 26.98% | 1.00% | -6.39% |
| Apr | 7.16% | -6.59% | -5.75% | 14.17% | 20.76% | 15.86% | 7.60% |
| May | 0.80% | -21.04% | -9.78% | -7.99% | 2.44% | -16.61% | -8.70% |
| Jun | 8.36% | 7.41% | 10.06% | 6.77% | 1.56% | 27.02% | 10.20% |
| Jul | -11.99% | 2.30% | 0.46% | 41.57% | 8.39% | -19.18% | 3.59% |
| Aug | 8.93% | 14.50% | -4.28% | 11.77% | -17.66% | 6.28% | 3.26% |
| Sep | 4.59% | 3.03% | -8.83% | -7.15% | 48.57% | -9.08% | 5.19% |
| Oct | 19.25% | 11.43% | -7.49% | -37.86% | 14.42% | 0.29%* | 0.01% |
| Nov | 1.03% | -6.66% | -14.51% | 15.13% | 15.57% | -- | 2.11% |
| Dec | 11.31% | 13.60% | 42.80% | -45.69% | 17.36% | -- | 7.88% |
| Total | 48.45% | -21.17% | -31.82% | -35.13% | 344.82% | 11.52% | 52.78% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $47.73
SMA 50: $52.51
SMA 200: $56.47
Current: $48.77
EMA 12: $47.97
EMA 26: $49.13
MACD: -1.1636 | Signal: 0.5005
BEARISH
ADX (14): 33.21
TREND
+DI: 13.74
−DI: 20.10
Momentum Oscillators
RSI (14): 48.47
NEUTRAL
Stoch %K: 57.60
Stoch %D: 50.57
Williams %R: -39.37
Volume & Volatility
BB Upper: $50.81
BB Lower: $44.65
NEUTRAL
OBV: 1,648,073
Vol SMA 20: 584,050
Vol ROC: 12.24%
ATR: $2.44
True Range: $1.64
HV 20: 53.4%
HV 30: 47.6%
HV 60: 41.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Here is my comprehensive stock analysis report for ANAB:
Executive Summary
Overall assessment: NEUTRAL (confidence level: 6/10) Key drivers: Litigation risks, patent expiration fears, and recent news sentiment impact. Primary risks: Patent expirations, regulatory issues, and competitive pressures. Recent news sentiment impact: Positive overall, but with a negative tone due to litigation concerns.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): BEARISH; Medium-term (1-3 months): NEUTRAL; Long-term (3-12 months): BULLISH
Support/Resistance Levels: SMA 20: $55.32, SMA 50: $57.98, Upper Bollinger Band: $59.61, Lower Bollinger Band: $51.03
Momentum Signals: RSI interpretation (overbought >70, oversold <30, neutral 30-70): NEUTRAL (54.26) MACD signal (bullish/bearish crossover): BEARISH Bollinger Bands position (squeeze, breakout, mean reversion): MEAN REVERSION Volume Analysis: Volume SMA 20: 458587.61; On-Balance Volume (OBV): 6141650.84; Volume Rate of Change: -68.72% (bearish)
News & Sentiment Analysis
Recent Headlines Summary: Recent news headlines have been mixed, with some positive developments and others emphasizing litigation risks. Sentiment Assessment: Positive overall sentiment, but with a negative tone due to litigation concerns.
Catalyst Identification: Litigation risks and patent expiration fears could impact the stock price in the near term.
Market Narrative: The recent news highlights ongoing litigation risks, which may weigh on the stock's short-term performance. However, the long-term trend remains bullish, driven by the company's pipeline and potential for continued growth.
Risk & Volatility Assessment
Beta Interpretation: Moderate risk relative to market (beta 0.96). Volatility Regime: Current volatility is moderate (-68.72% volume rate of change). Options Market Signals: IV rank: 2.2% (Low); Put/Call Volume Ratio: 2.83 (Bearish sentiment).
Market Context & Positioning
Sector Performance: ANAB's sector has been performing well, but the company's stock price has lagged behind. Institutional Activity: Institutional interest is moderate, with some buying and selling activity observed.
Correlation Analysis: The stock's correlation with the market is relatively low (R-squared: 0.16).
Key Levels & Action Items
Critical Price Levels: SMA 20: $55.32, Upper Bollinger Band: $59.61, Lower Bollinger Band: $51.03.
Breakout/Breakdown Levels: The stock price may break out above the upper Bollinger Band or below the lower Bollinger Band to indicate significant moves.
Time-Sensitive Catalysts: Upcoming litigation developments and patent expiration risks could impact the stock's short-term performance.
Risk Management: Investors should monitor the company's litigation progress and patent expiration risks, considering stop-loss levels and position sizing considerations.
Please note that this analysis is based on the provided data and may not reflect the actual stock price or market conditions.
Generated
News
All ANAB news →
First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged. The post Why This IPO Stock, An AnaptysBio Spinoff, Just Surged appeared first on Investor's Business Daily .
Earnings History
18 of 21 under expected move
Avg Expected Move
17.75%
Avg Actual Move
6.69%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-25 | After-Close | 34.45% | 10.47% | 0.30x | Within |
| 2021-05-04 | After-Close | 22.09% | 3.74% | 0.17x | Within |
| 2021-08-09 | After-Close | 1.47% | 2.35% | 1.60x | Exceeded |
| 2022-03-07 | After-Close | 55.27% | 2.73% | 0.05x | Within |
| 2022-08-08 | After-Close | 4.28% | 5.63% | 1.32x | Exceeded |
| 2023-01-05 | After-Close | 5.30% | 23.10% | 4.36x | Exceeded |
| 2023-05-11 | After-Close | 11.22% | 6.31% | 0.56x | Within |
| 2023-08-07 | After-Close | 13.06% | 2.65% | 0.20x | Within |
| 2023-11-02 | After-Close | 16.36% | 8.21% | 0.50x | Within |
| 2024-01-05 | After-Close | 12.88% | 5.32% | 0.41x | Within |
| 2024-03-11 | After-Close | 13.49% | 11.61% | 0.86x | Within |
| 2024-05-09 | After-Close | 16.39% | 10.75% | 0.66x | Within |
| 2024-08-05 | After-Close | 15.29% | 0.90% | 0.06x | Within |
| 2024-11-05 | After-Close | 12.32% | 11.72% | 0.95x | Within |
| 2025-02-27 | After-Close | 21.04% | 2.56% | 0.12x | Within |
| 2025-05-05 | After-Close | 20.38% | 2.94% | 0.14x | Within |
| 2025-08-06 | Pre-Market | 12.56% | 4.85% | 0.39x | Within |
| 2025-11-04 | Pre-Market | 25.04% | 3.61% | 0.14x | Within |
| 2026-01-09 | Pre-Market | 11.19% | 1.99% | 0.18x | Within |
| 2026-03-03 | After-Close | 17.04% | 14.61% | 0.86x | Within |
| 2026-05-12 | After-Close | 31.64% | 4.41% | 0.14x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ANAB Options Activity & IV Rank
ANAB IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 86.1%
7-DTE IV: —
Expected Move: $44.70
7-DTE Move: $44.70
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 47
Put Volume: 78
P/C Volume: 1.66
BEARISH
Call OI: 564
Put OI: 855
P/C OI: 1.516
Total OI: 1,419
ATM Options Pricing
ATM Call: $42.20
ATM Put: $2.50
Call %: 86.5%
Put %: 5.1%
Chain Summary
Chain Volume: 1,681
Chain OI: 3,225
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 56th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
56%
vs own history
GEX tilt
+0.21
OI-weighted, today
Vanna tilt
+0.71
δ-sensitivity to IV
Charm tilt
-0.65
δ-decay vs time
Vanna tilt +0.71: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.65: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 8 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 82.8% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)75.9HighOct 26
Straddle Price (30 DTE)$44.70Oct 26
Beta Analysis
Risk Metrics
Beta: 0.9204
Alpha: 43.72%
Correlation: 0.1763
R-Squared: 3.1%
Stock Volatility: 66.5%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
ANAB Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 28,819,250 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$3.48M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.62M | 46.51% | 2026-06-30 |
| 2 | Millennium Management LLC Custodian | $1.01M | 29.07% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $580.50K | 16.67% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $209.25K | 6.01% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $60.75K | 1.74% | 2026-06-30 |
3 filers$6.57M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $4.89M | 74.44% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $958.50K | 14.58% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $722.25K | 10.99% | 2026-06-30 |
ANAB Insider Trading (Form 4)
Latest: 2026-10-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Hollings Renton | Director | Mixed | — | $33.95 | -$159.2K | EDGAR |
| 2026-09-17 | John A Orwin | Director | Exer (M) | +1,300 | — | EDGAR | |
| 2026-08-07 | Daniel Faga | President, CEO | Grant (A) | +53,334 RSU | — | EDGAR | |
| 2026-08-07 | Paul F. Lizzul | Chief Medical Officer | Grant (A) | +16,667 RSU | — | EDGAR | |
| 2026-08-07 | Daniel Faga | President, CEO | Grant (A) | +53,334 RSU | — | EDGAR | |
| 2026-08-07 | Paul F. Lizzul | Chief Medical Officer | Grant (A) | +16,667 RSU | — | EDGAR | |
| 2026-06-17 | John A Orwin | Director | Exer (M) | +6,030 | — | EDGAR | |
| 2026-06-17 | Hollings Renton | Director | Exer (M) | +6,030 | — | EDGAR | |
| 2026-06-17 | John P. Schmid | Director | Exer (M) | +6,030 | — | EDGAR | |
| 2026-05-13 | Owen Hughes | Director | Grant (A) | +11,250 RSU | — | EDGAR | |
| 2026-05-13 | Christopher M. Murphy | Chief Financial Officer | Grant (A) | +25,765 RSU | — | EDGAR | |
| 2026-04-29 | Susannah Gray | Director | Grant (A) | +11,250 RSU | — | EDGAR | |
| 2026-04-23 | Daniel Faga | President, CEO | Disp (D) | −11,000 opt | — | EDGAR | |
| 2026-04-22 | John A Orwin | Director | Mixed | — | — | EDGAR | |
| 2026-04-22 | John P. Schmid | Director | Mixed | — | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ANAB Insider Holdings
12 insiders · @ $48.77
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | Director | 7,880,094 | $384.31M | $92.83M | 6 | 2025-01-02 |
| 2 | Daniel Faga | President, CEO | 505,862 | $24.67M | -$6.34M | 17 | 2026-08-07 |
| 3 | Paul F. Lizzul | Chief Medical Officer | 42,088 | $2.05M | -$895.2K | 22 | 2026-08-07 |
| 4 | John P. Schmid | Director | 37,652 | $1.84M | -$1.16M | 18 | 2026-06-17 |
| 5 | Dennis Mulroy | CHIEF FINANCIAL OFFICER | 24,367 | $1.19M | -$2.31M | 20 | 2026-01-09 |
| 6 | Eric J Loumeau | CHIEF LEGAL OFFICER | 22,835 | $1.11M | -$4.40M | 30 | 2026-02-13 |
| 7 | John A Orwin | Director | 17,995 | $877.6K | $0 | 11 | 2026-09-17 |
| 8 | Rita Jain | Director | 11,864 | $578.6K | $0 | 6 | 2026-01-08 |
| 9 | Magda Marquet | Director | 11,640 | $567.7K | -$530.5K | 10 | 2026-01-16 |
| 10 | Hollings Renton | Director | 10,995 | $536.2K | -$1.62M | 20 | 2026-10-02 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ANAB Board & Officers
As of SEC filings through Oct 2, 2026Directors 6
- Hollings Renton · since Jan 25, 2017
- John P. Schmid · since Jan 25, 2017
- Daniel Faga · since Nov 26, 2021
- John A Orwin · since Sep 15, 2023
- Susannah Gray · since Mar 26, 2026
- Owen Hughes · since May 11, 2026
Officers 3
- Daniel Faga · President, CEO · listed since Jan 2025
- Christopher M. Murphy · Chief Financial Officer · since May 11, 2026
- Paul F. Lizzul · Chief Medical Officer · since Jul 31, 2020
Changes in the last 10 years (77)
| May 11, 2026 | Owen Hughes became a director |
| May 11, 2026 | Christopher M. Murphy became Chief Financial Officer |
| Apr 20, 2026 | The company announced the departure of Rita Jain from the board in an SEC filing |
| Apr 20, 2026 | The company announced the departure of Magda Marquet from the board in an SEC filing |
| Apr 20, 2026 | The company announced the departure of J. Anthony Ware from the board in an SEC filing |
| Apr 20, 2026 | The company announced the departure of Dennis M Fenton from the board in an SEC filing |
| Mar 26, 2026 | The company announced the departure of Eric J Loumeau as Chief Legal Officer in an SEC filing |
| Mar 26, 2026 | The company announced the departure of Dennis Mulroy as Chief Financial Officer in an SEC filing |
| Mar 26, 2026 | Susannah Gray became a director |
| Jan 7, 2025 | Daniel Faga listed as President, CEO (previously CEO) in SEC filings |
| Jan 2, 2025 | EcoR1 Capital, LLC first listed as a director in an SEC filing |
| Jan 5, 2024 | Daniel Faga listed as CEO (previously Interim CEO) in SEC filings |
| Sep 18, 2023 | Eric J Loumeau listed as Chief Legal Officer (previously COO, General Counsel) in SEC filings |
| Sep 15, 2023 | John A Orwin became a director |
| Apr 3, 2023 | Rita Jain became a director |
| Apr 1, 2023 | The company announced the departure of Laura Hamill from the board in an SEC filing |
| May 9, 2022 | EcoR1 Capital, LLC no longer listed as a director in SEC filings |
| Apr 25, 2022 | The company announced the departure of James N Topper from the board in an SEC filing |
| Mar 23, 2022 | Daniel Faga first listed as Interim CEO in an SEC filing |
| Mar 20, 2022 | The company announced the departure of Hamza Suria from the board in an SEC filing |
| Mar 20, 2022 | The company announced the departure of Hamza Suria as President, CEO in an SEC filing |
| Nov 26, 2021 | Daniel Faga became a director |
| Apr 27, 2021 | EcoR1 Capital, LLC first listed as a director in an SEC filing |
| Apr 8, 2021 | Oleg Nodelman became a director |
| Apr 8, 2021 | Oleg Nodelman became a 10% owner |
| Jan 18, 2021 | Magda Marquet became a director |
| Jan 4, 2021 | EcoR1 Capital, LLC became a 10% owner |
| Jul 31, 2020 | Paul F. Lizzul became Chief Medical Officer |
| Jul 15, 2020 | Eric J Loumeau listed as COO, General Counsel (previously General Counsel & Interim CFO) in SEC filings |
| Jul 13, 2020 | Dennis Mulroy became Chief Financial Officer |
| Sep 24, 2019 | Laura Hamill became a director |
| Aug 20, 2019 | Eric J Loumeau listed as General Counsel & Interim CFO (previously General Counsel) in SEC filings |
| Aug 6, 2018 | Eric J Loumeau became General Counsel |
| May 15, 2018 | Patrick J Heron reported in an SEC filing no longer being a 10% owner |
| May 15, 2018 | Nathan R Every reported in an SEC filing no longer being a 10% owner |
| May 15, 2018 | Nader J Naini reported in an SEC filing no longer being a 10% owner |
| May 15, 2018 | Frazier Healthcare VII-A, L.P. reported in an SEC filing no longer being a 10% owner |
| May 15, 2018 | Frazier Healthcare VII, L.P. reported in an SEC filing no longer being a 10% owner |
| May 15, 2018 | Frazier Healthcare V, LP reported in an SEC filing no longer being a 10% owner |
| May 15, 2018 | Fhm Vii, L.p. reported in an SEC filing no longer being a 10% owner |
| May 15, 2018 | Fhm Vii, L.l.c. reported in an SEC filing no longer being a 10% owner |
| May 15, 2018 | Fhm V, LP reported in an SEC filing no longer being a 10% owner |
| May 15, 2018 | Fhm V, LLC reported in an SEC filing no longer being a 10% owner |
| May 15, 2018 | Alan D Frazier reported in an SEC filing no longer being a 10% owner |
| Mar 5, 2018 | Dennis M Fenton became a director |
| Aug 22, 2017 | J. Anthony Ware became a director |
| Aug 21, 2017 | Novo Holdings A/S reported in an SEC filing no longer being a 10% owner |
| Jul 28, 2017 | Stephen Lawrence Tomlin reported in an SEC filing no longer being a 10% owner |
| Jul 28, 2017 | Kevin J Kinsella reported in an SEC filing no longer being a 10% owner |
| Jul 28, 2017 | Avalon Ventures VII L P reported in an SEC filing no longer being a 10% owner |
| Jan 25, 2017 | Stephen Lawrence Tomlin became a 10% owner |
| Jan 25, 2017 | Patrick J Heron became a 10% owner |
| Jan 25, 2017 | Novo Holdings A/S became a 10% owner |
| Jan 25, 2017 | Nicholas Lydon became a director |
| Jan 25, 2017 | Nathan R Every became a 10% owner |
| Jan 25, 2017 | Nader J Naini became a 10% owner |
| Jan 25, 2017 | Matthew Moyle became Chief Scientific Officer |
| Jan 25, 2017 | Marco Londei became Chief Medical Officer |
| Jan 25, 2017 | Kevin J Kinsella became a 10% owner |
| Jan 25, 2017 | John P. Schmid became a director |
| Jan 25, 2017 | James N Topper became a director |
| Jan 25, 2017 | James N Topper became a 10% owner |
| Jan 25, 2017 | James A Schoeneck became a director |
| Jan 25, 2017 | Hollings Renton became a director |
| Jan 25, 2017 | Hamza Suria became a director |
| Jan 25, 2017 | Hamza Suria became President, CEO |
| Jan 25, 2017 | Frazier Healthcare VII-A, L.P. became a 10% owner |
| Jan 25, 2017 | Frazier Healthcare VII, L.P. became a 10% owner |
| Jan 25, 2017 | Frazier Healthcare V, LP became a 10% owner |
| Jan 25, 2017 | Fhm Vii, L.p. became a 10% owner |
| Jan 25, 2017 | Fhm Vii, L.l.c. became a 10% owner |
| Jan 25, 2017 | Fhm V, LP became a 10% owner |
| Jan 25, 2017 | Fhm V, LLC became a 10% owner |
| Jan 25, 2017 | Dominic Piscitelli became Chief Financial Officer |
| Jan 25, 2017 | Carol Giltner Gallagher became a director |
| Jan 25, 2017 | Avalon Ventures VII L P became a 10% owner |
| Jan 25, 2017 | Alan D Frazier became a 10% owner |
Not reported recently (9)
- EcoR1 Capital, LLC · Last reported as a 10% owner in an SEC filing dated Jan 2, 2025
- Oleg Nodelman · Last reported as a director in an SEC filing dated Jan 2, 2025
- James N Topper · Last reported as a 10% owner in an SEC filing dated Jan 10, 2023
- Marco Londei · Last reported as Chief Medical Officer in an SEC filing dated Dec 10, 2019
- Nicholas Lydon · Last reported as a director in an SEC filing dated Feb 11, 2019
- Dominic Piscitelli · Last reported as Chief Financial Officer in an SEC filing dated Feb 11, 2019
- Carol Giltner Gallagher · Last reported as a director in an SEC filing dated Feb 6, 2018
- James A Schoeneck · Last reported as a director in an SEC filing dated Feb 6, 2018
- Matthew Moyle · Last reported as Chief Scientific Officer in an SEC filing dated Feb 28, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ANAB Proposed Insider Sales (Form 144)
Latest: 2026-10-01
? Form 144 Guide
Last 30d:
1 filing
· $249K notice value
· Last 90d:
1 filing
· $249K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
HOLLINGS C RENTON (1, $249K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-01 | HOLLINGS C RENTON | Director | 5,000 | $249.4K | 2026-10-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-13 | JOE ANTHONY WARE | Director | 10,694 | $718.3K | 2026-07-13 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-30 | JOE ANTHONY WARE | Director | 6,030 | $408.8K | 2026-06-30 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-29 | DENNIS MULROY | Officer | 9,476 | $601.2K | 2026-06-29 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-26 | DENNIS MULROY | Officer | 10,000 | $608.2K | 2026-06-26 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-17 | DENNIS MULROY | Officer | 850 | $51.0K | 2026-06-17 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-16 | DENNIS MULROY | Officer | 1,265 | $75.9K | 2026-06-16 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-15 | DENNIS MULROY | Officer | 20,000 | $1.15M | 2026-06-15 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-12 | DENNIS MULROY | Officer | 20,000 | $1.11M | 2026-06-12 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-11 | DENNIS MULROY | Officer | 35,000 | $1.85M | 2026-06-11 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
66 ETFs hold ANAB
25 shown · $194.65M total exposure · 0.04% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.32% | $33.1M | $10.4B | 2026-10-23 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $32.6M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $24.7M | $74.6B | 2026-10-23 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $12.1M | — | 2026-09-30 |
| 5 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.10% | $10.3M | $10.7B | 2026-10-23 |
| 6 | PBE Invesco Biotechnology & Genome ETF | Invesco | 2.28% | $9.8M | — | 2026-10-24 |
| 7 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.07% | $9.1M | $13.7B | 2026-10-23 |
| 8 | BRES Burney U.S. Equity Select ETF | Nport | 1.18% | $7.9M | — | 2026-07-31 |
| 9 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.02% | $7.0M | — | 2026-10-23 |
| 10 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.50% | $6.6M | $1.3B | 2026-10-23 |
| 11 | BRNY Burney U.S. Factor Rotation ETF | Nport | 1.14% | $6.6M | — | 2026-07-31 |
| 12 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.03% | $5.9M | — | 2026-09-30 |
| 13 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.02% | $5.3M | — | 2026-05-31 |
| 14 | USVM VictoryShares US Small Mid Cap Value Momentum ETF | Nport | 0.19% | $3.4M | — | 2026-06-30 |
| 15 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $2.7M | — | 2026-09-30 |
| 16 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.03% | $2.5M | — | 2026-10-23 |
| 17 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.18% | $2.5M | $1.4B | 2026-10-23 |
| 18 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.13% | $2.4M | — | 2026-10-23 |
| 19 | FSMD Fidelity Small-Mid Multifactor ETF | Fidelity | 0.09% | $2.2M | $2.5B | 2026-10-23 |
| 20 | CANC Tema Oncology ETF | Nport | 0.99% | $1.7M | — | 2026-05-31 |
| 21 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.4M | $96.5B | 2026-10-23 |
| 22 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.22% | $1.3M | — | 2026-10-26 |
| 23 | OMFS Invesco Russell 2000 Dynamic Multifactor ETF | Invesco | 0.45% | $1.2M | — | 2026-10-24 |
| 24 | DWAS Invesco Dorsey Wright SmallCap Momentum ETF | Nport | 0.28% | $1.2M | — | 2026-05-31 |
| 25 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.04% | $1.1M | — | 2026-07-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.96
TTM Revenue
$232.39M
TTM Net Income
$-26.79M
TTM Op. Cash Flow
$4.48M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $25.56M | $-52.88M | $-1.84 | $-25.92M |
| Q4 '25 | 2025-12-31 | $108.25M | $49.61M | $1.70 | $98.00M |
| Q3 '25 | 2025-09-30 | $76.32M | $15.11M | $0.52 | $-27.36M |
| Q2 '25 | 2025-06-30 | $22.26M | $-38.63M | $-1.34 | $-40.24M |
| Q1 '25 | 2025-03-31 | $27.77M | $-39.33M | $-1.28 | $-10.70M |
| Q4 '24 | 2024-12-31 | $43.11M | $-21.78M | $-0.66 | $-66.67M |
| Q3 '24 | 2024-09-30 | $30.02M | $-32.85M | $-1.14 | $-10.09M |
| Q2 '24 | 2024-06-30 | $10.97M | $-46.66M | $-1.71 | $-21.32M |
| Q1 '24 | 2024-03-31 | $7.18M | $-43.94M | $-1.64 | $-37.25M |
| Q4 '23 | 2023-12-31 | $9.01M | $-42.21M | $-1.59 | $-34.35M |
| Q3 '23 | 2023-09-30 | $3.32M | $-37.31M | $-1.41 | $-36.47M |
| Q2 '23 | 2023-06-30 | $3.46M | $-39.84M | $-1.50 | $-25.41M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-12
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
110.26
P/S
6.05
EV/EBITDA
27.99
EV/Sales
4.98
ROE
-210.1%
ROA
-8.1%
Div Yield
0.00%
FCF Yield
0.32%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$1.41B
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
5.24M
SI % of Float
29.70%
Days to Cover
8.19
Short Vol Ratio
36.6%
Free Float
17.63M
Float %
59.0%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-09-22